Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21498991 | 1.00 | SIGMAR1 (1.00) | SIGMAR1TMEM97KDM4EALDH1A1GAA | |
| SCHEMBL16408641 | 1.00 | SIGMAR1 (1.00) | SIGMAR1TMEM97KDM4EALDH1A1GAA | |
| SCHEMBL18099265 | 1.00 | SIGMAR1 (1.00) | SIGMAR1TMEM97KDM4EALDH1A1GAA | |
| SCHEMBL18100556 | 0.91 | SIGMAR1 (1.00) | SIGMAR1TMEM97 | |
| SCHEMBL18099240 | 0.91 | SIGMAR1 (1.00) | SIGMAR1TMEM97 | |
| SCHEMBL16408644 | 0.87 | SIGMAR1 (0.80) | SIGMAR1TMEM97 | |
| SCHEMBL18100561 | 0.80 | SIGMAR1 (1.00) | SIGMAR1TMEM97 | |
| SCHEMBL18099266 | 0.80 | SIGMAR1 (1.00) | SIGMAR1TMEM97 | |
| SCHEMBL16408516 | 0.80 | SIGMAR1 (1.00) | SIGMAR1TMEM97 | |
| SCHEMBL16408580 | 0.80 | SIGMAR1 (1.00) | SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115345-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | UNIV TEXAS (US) | 2020-04-16 | — | — | US | disclosed |
| US-10450275-B2 | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-22 | — | — | US | disclosed |
| WO-2015009742-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115345-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | ELAVL1, ADH1A, NGF | SIGMAR1 423/4885TMEM97 1532/4885KDM4E 2334/4885 |
| US-10450275-B2 | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain | ELAVL1, ADH1A, NGF | SIGMAR1 423/4885TMEM97 1532/4885KDM4E 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.